A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Wisconsin, Madison
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Centre Antoine Lacassagne
Universität des Saarlandes
University of Chicago
Mayo Clinic
M.D. Anderson Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
University of Birmingham
Memorial Sloan Kettering Cancer Center
University of Nebraska
Alliance for Clinical Trials in Oncology
Ruijin Hospital
Rush University Medical Center
Weill Medical College of Cornell University
Universität des Saarlandes
Alliance for Clinical Trials in Oncology
Universität des Saarlandes
Universität des Saarlandes
Universität des Saarlandes
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Stanford University
Martin-Luther-Universität Halle-Wittenberg
Martin-Luther-Universität Halle-Wittenberg
Martin-Luther-Universität Halle-Wittenberg
Hunan Cancer Hospital
Alliance for Clinical Trials in Oncology
Swiss Cancer Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Lymphoma Study Association
Stanford University
M.D. Anderson Cancer Center
Lund University Hospital
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alliance for Clinical Trials in Oncology
University of Miami
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology